Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
评估G1疗法：来自5位金融分析师的见解
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX) in the last three months.
在过去三个月中，有5位分析师公布了对G1 Therapeutics（纳斯达克股票代码：GTHX）的评级，提供了从看涨到看跌的不同视角。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表汇总了他们最近的评级，阐明了过去30天内情绪的变化，并将其与前几个月进行了比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.4, a high estimate of $12.00, and a low estimate of $4.00. This upward trend is apparent, with the current average reflecting a 9.47% increase from the previous average price target of $9.50.
分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为10.4美元，最高估计为12.00美元，低估值为4.00美元。这种上升趋势显而易见，当前的平均价格较之前的平均目标价9.50美元上涨了9.47％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
In examining recent...
在研究...
登录免费看全文
登录/注册